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Abstract. Renal fibrosis is the major determinant in progression of kidney disease and results from an
inappropriate response to acute and chronic kidney injury. Transforming growth factor (TGF)-β1 is the
driving force behind renal fibrosis and has since long been regarded as the key factor to be targeted in
prevention and treatment of renal fibrosis. Despite the impressive results obtained in experimental renal
fibrosis, TGF-β1 blockade has not yet translated into an effective and safe therapeutic in human patients.
Therefore, it remains important to explore the role of additional growth factors which are involved in
renal regeneration and fibrosis. Recently, bone morphogenetic protein (BMP)-7 and connective tissue
growth factor (CTGF) have both emerged as novel modulators of profibrotic TGF-β1 activity. The
expression of BMP-7 is decreased in various models of renal disease, while CTGF is strongly upregulated
in experimental and human renal fibrosis. In experimental kidney injury, administration of BMP-7 or
inhibition of CTGF have been sufficient to result in striking improvement of renal function and structure.
This review summarizes the current knowledge of BMP-7 and CTGF in the kidney, and discusses their
therapeutic potential in renal fibrosis.
KEY WORDS: bone morphogenetic protein-7; connective tissue growth factor; diabetic nephropathy;
renal fibrosis; transforming growth factor-β.
BACKGROUND
Renal Fibrosis
Renal fibrosis is the major determinant in progression of
kidney disease and results from a general set of responses to
acute and chronic kidney injury, irrespective of the initial
cause. Renal fibrosis is characterized by excessive accumula-
tion of extracellular matrix (ECM) components leading to
glomerulosclerosis, tubulointerstitial fibrosis, inflammatory
infiltration, loss of renal parenchyma, and renal vascular
changes. The origin of matrix production in the kidney is not
completely understood, but might include activation of
resident fibroblasts, epithelial and mesangial cells, migration
of haematopoietic or mesenchymal stem cells from the bone
marrow, migration of periadventitial cells, and epithelial-
to-mesenchymal transition (EMT) of tubular epithelial cells
(1,2).
Fibrosis, Response to Injury, and Growth Factors
Under physiological conditions, local damage or altered
environmental factors will result in an appropriate response to
injury of the affected kidney resulting in minimal scarring and
optimal repair and functional recovery. However, in many
instances, inappropriate response to injury occurs, favoring
scar formation over repair. This contributes significantly to
progressive renal fibrosis, and subsequently to end-stage
renal failure. The precise molecular mechanisms of renal
fibrosis have not been fully elucidated, but renal response to
injury is considered to be determined by the expression level of
certain growth factors. Transforming growth factor (TGF)-β1
is generally regarded as the key mediator in the develop-
ment of renal fibrosis (3). Although many therapeutic
approaches have been explored to inhibit TGF-β1 activity
in experimental models of renal disease, thus far no anti-
TGF-β1 therapy has been applied in a clinical setting (4).
Therefore, it remains important to explore the role of
additional growth factors which are involved in renal
regeneration and fibrosis. In this respect, bone morphoge-
netic protein (BMP)-7 and connective tissue growth factor
(CTGF) might be attractive novel targets in the treatment of
renal fibrosis.
TGF-Β1 IS THE DRIVING FORCE BEHIND RENAL
FIBROSIS
Transforming Growth Factor-β1 (TGF-β1)
TGF-β1 is a member of the TGF-β superfamily, which
consists of more than 30 growth factors, including BMPs,
inhibins, and activins (5). Members of the TGF-β superfamily
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signal through binding to type I and type II serine/threonine
kinase receptors. Upon ligand binding and receptor complex
activation, receptor regulated (R)-Smads are phosphorylated.
Phophorylated R-Smads bind to their common partner
Smad4, and subsequently translocate into the nucleus where
they act as transcription factors. The specificity of the signal is
mainly determined by the type I receptor, also known as
activin receptor-like kinase (ALK), and the R-Smads. In
general, TGF-βs bind ALK5 and activate Smad2 and -3,
while BMPs bind ALK2, -3, and -6, and activate Smad1, -5,
and -8 (6).
In mammals, three isoforms of TGF-β (TGF-β1, TGF-
β2, and TGF-β3) have been identified, which are encoded by
genes lying on separate chromosomes, but share a high
degree of homology. Since all TGF-β isoforms also show
comparable in vitro biological activities and signal through
the same set of receptors, it has been suggested that they have
equal biological activity in vivo. However, studies with TGF-β
isoform-specific knockout mice have revealed that each TGF-
β isoform exerted specific and non-compensated functions,
which might relate to their individual expression regulation
and distribution (7). The effects of TGF-β1 are multifunc-
tional and, in addition to its fibrogenic role as main inducer of
ECM production, the functions of TGF-β1 also include
regulation of cell growth, cell differentiation, cytokine pro-
duction, and immune cell modulation (8–10).
TGF-β1 Expression in Renal Fibrosis
The relevance of TGF-β1 in renal disease was first
reported in a landmark study by Border et al., who provided
direct evidence for a causal role of TGF-β1 in ECM
accumulation in experimental acute mesangial proliferative
glomerulonephritis (11). Subsequently, upregulation of TGF-
β1 expression has been demonstrated in a wide variety of
other experimental diseases associated with renal fibrosis,
including anti-glomerular basement membrane disease, ob-
structive nephropathy, hypertensive nephrosclerosis, and
diabetic nephropathy (12–15). In human renal biopsies,
upregulation of TGF-β1 and isoforms was observed in
glomerular and tubulointerstitial diseases characterized by
ECM accumulation, but not in renal disorders where ECM
accumulation was not a feature (15–17). In addition, levels of
circulating and/or urinary TGF-β1 protein were shown to be
elevated in patients with renal fibrotic diseases like chronic
allograft nephropathy, focal segmental glomerulosclerosis,
and diabetic nephropathy (18–20).
Inhibition of TGF-β1 Activity
Several therapeutic strategies have been applied success-
fully to inhibit profibrotic TGF-β1 activity in experimental
models of renal fibrosis. These approaches include inhibition
of TGF-β1 by neutralizing antibodies, antisense oligodeoxy-
nucleotides, soluble TGF-β1 receptors, and blockade of TGF-
β1 activation by decorin (11,21–24). Recently, the use of a
small molecule inhibitor of the specific TGF-β receptor
ALK5 proved to be effective in suppression of renal fibrosis
in rat models of puromycin-induced nephritis and obstructive
nephropathy (25,26). In addition, a novel small molecule
inhibitor selective for ALK5 and the TGF-β type II receptor
was capable of reducing renal fibrosis in diabetic db/db mice
(27).
Despite the impressive results obtained in experimental
renal fibrosis, TGF-β1 blockade has not yet translated into an
effective and safe therapeutic in human patients. This might
relate to concern about possible adverse effects of TGF-β1
inhibition. The observation that TGF-β1 knockout mice
display an autoimmune and hyperinflammatory phenotype,
while transgenic mice overexpressing TGF-β1 are protected
from renal inflammation, underscores the important role of
TGF-β1 in controlling accurate levels of inflammatory
activity (28,29). Furthermore, studies in which inhibition of
TGF-β1 activity resulted in enhanced tumorigenesis, both in
TGF-β1+/− mice and in nude mice injected with a dominant-
negative mutant TGF-β type II receptor, confirms that TGF-
β1 also has relevant functions in anti-proliferation and tumor
suppression (30,31). Thus, considering the multifunctional
biological activities of TGF-β1, it is important to explore
therapeutic strategies that are aimed at targeting the
downstream effectors or the signaling pathway of TGF-β1
that specifically mediates its fibrogenic action. In this respect,
BMP-7 and CTGF have both appeared as promising targets
for modulation of profibrotic TGF-β1 activity.
BMP-7 IS DOWNREGULATED IN RENAL FIBROSIS
Bone Morphogenetic Protein-7 (BMP-7; OP-1)
The TGF-β superfamily comprises over twenty BMPs, of
which BMP-7 (also called osteogenic protein-1 or OP-1) is the
most prominent member involved in renal development and
disease. BMPs are differentially expressed throughout devel-
opment, and it was demonstrated that in particular BMP-7
and BMP-4 are important in the developing kidney. Initially,
BMP-7 is expressed in the ureteric bud. Later in develop-
ment, BMP-7 is also found in the metanephric mesenchyme,
early tubules, and eventually in the podocytes of mature
glomeruli (32–35). The relevance of BMP-7 in renal devel-
opment was observed in homozygous BMP-7 knockout mice,
which showed reduction in branching of the ureteric bud and
loss of metanephric mesenchyme, resulting in severe renal
hypoplasia (32). In the adult kidney, BMP-7 is expressed in
glomerular podocytes, the thick ascending limb, the distal
convoluted tubule, and most strongly in the collecting duct
(36).
BMP-7 Expression in Renal Fibrosis
In contrast to the consistent upregulation of TGF-β1 in
models of experimental and human renal fibrosis, expression
of BMP-7 was shown to be markedly reduced in experimental
diseases associated with renal fibrosis. For example, the
expression of BMP-7 mRNA and protein was downregulated
after ischemia-reperfusion injury, unilateral ureteral obstruc-
tion (UUO), pyelonephritis, chronic allograft nephropathy,
and in genetic murine models of Alport syndrome and lupus
nephritis (37–43). In streptozotocin-induced diabetic rats,
renal expression of BMP-7 was decreased by more than
90%, and this was accompanied by downregulation of the
BMP type II receptor and the type I receptor ALK2 (44).
Decrease of BMP-7 expression was also evidenced in mouse
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podocytes cultured under high glucose, and in renal biopsies
of patients with diabetic nephropathy (45,46). Thus far, the
latter study is the only report available demonstrating
decrease of BMP-7 expression in human patients. In addition,
loss of BMP-7 signaling activity, as illustrated by lower
phosphorylated Smad1/5 protein levels, was observed in
experimental nephrotoxic serum nephritis and diabetic ne-
phropathy (47,48).
EFFICACY OF BMP-7 AS AN ANTIFIBROTIC DRUG
In Vitro Antifibrotic Effects of BMP-7 in Renal Cells
The function of BMP-7 in the adult kidney has not been
revealed completely, but recent evidence suggest that endog-
enous BMP-7 might function as a regulator of kidney
homeostasis and regeneration by maintaining a differentiated
epithelial phenotype of tubular epithelial cells (48,49). In vitro
studies have demonstrated that BMP-7 is a potent antagonist
of TGF-β1 mediated effects on renal cells. In particular,
BMP-7 proved to be a potent inhibitor of TGF-β1 induced
EMT of proximal tubular epithelial cells (47). Other protec-
tive effects of BMP-7 in proximal tubular epithelial cells
include inhibition of TGF-β1 production, decrease of pro-
inflammatory genes and chemoattractants, and inhibition of
EMT induced by multiple myeloma light chains (36,50,51).
Also in mesangial cells and podocytes, BMP-7 was able to
inhibit adverse effects caused by TGFβ1, aldosterone, or high
glucose (45,46,52,53). The remarkable potential of BMP-7
even to reverse fibrosis was demonstrated by its ability to
induce formation of epithelial cell aggregates in cultures of
adult renal fibroblasts, which was accompanied by acquisition
of E-cadherin expression and decreased motility, indicating
that true mesenchymal-to-epithelial transition (MET) might
also be achieved (54).
BMP-7 Therapy in Experimental Fibrosis
In vivo evidence for antifibrotic properties of BMP-7 was
first demonstrated by Vukicevic et al. (55), who showed that
BMP-7 reduced severity of renal injury after ischemia-
reperfusion by temporary bilateral renal artery occlusion in
rats. In this study, intravenously administered BMP-7 pre-
served kidney function as evidenced by reduced blood urea
nitrogen and serum creatinine, and it also attenuated
proteinuria while increasing survival rate. In subsequent
studies, others showed that BMP-7 prevented renal fibro-
genesis associated with ureteral obstruction, and effectively
restored renal function if administered during the progression
of this fibrotic disease (39,56).
The in vitro potential of BMP-7 to inhibit EMT and to
induce MET was confirmed in a mouse model of chronic
injury caused by nephrotoxic serum nephritis, in which
reversal of renal fibrosis was observed even with BMP-7
therapy starting several weeks after the occurrence of damage
(47,54). The same investigators also showed that BMP-7
therapy could attenuate progression of renal disease in
genetic mouse models of lupus nephritis and Alport syn-
drome (43). However, the therapeutic potential of BMP-7 has
been investigated most extensively in experimental diabetic
nephropathy, which in human patients is the leading cause of
end-stage renal disease. In streptozotocin-induced diabetic
rats, both glomerular and tubulointerstitial damage as well as
albuminuria were significantly attenuated by BMP-7 therapy
in a dose-dependent manner (57). A similar effect on
structural changes was observed after BMP-7 treatment in
diabetic CD1 mice. In that study, BMP-7 had no effect on
albuminuria (58). However, in diabetic transgenic mice over-
expressing BMP-7 in podocytes and proximal tubuli, the
severity of glomerulosclerosis, interstitial fibrosis, and albu-
minuria were all markedly decreased (48).
The therapeutic potential of BMP-7 reaches beyond its
efficacy in the kidney. In the liver, BMP-7 treatment
attenuated CCl4-induced fibrosis by inhibition of hepato-
cyte-to-fibroblast transition, and it facilitated hepatocyte
regeneration, and accelerated restoration of liver function in
mice after partial hepatectomy (59,60). However, the anti-
fibrotic effect of BMP-7 in the liver remains controversial,
since one study has recently demonstrated that BMP-7
expression was upregulated in the cirrhotic human liver, and
that BMP-7 could induce production of collagen and fibro-
nectin in hepatic stellate cells (61). In rats with inflammatory
bowel disease, systemic administration of BMP-7 led to less
severe colitis with preserved histology and suppression of
proinflammatory and profibrogenic genes (62). Administra-
tion of BMP-7 also inhibited the progression of cardiac
fibrosis in mouse models of pressure overload and chronic
allograft rejection, probably by counteracting TGF-β1 in-
duced endothelial-to-mesenchymal transition (63). In line
with its strong osteogenic properties, intraperitoneal injection
of BMP-7 was successful in treatment of renal osteodystrophy
and adynamic bone disorder in mice (64,65). Paradoxically,
however, BMP-7 inhibited vascular calcification in a murine
model of renal failure associated atherosclerosis, rendering it
almost a panacea (66).
Local BMP-7 therapy is currently under study in human
orthopedic patients to improve healing of fractures and non-
unions, and for spinal fusion (67). Thus far, clinical trials with
BMP-7 have not been performed in renal diseases, and it
remains to be established whether ectopic bone formation or
other adverse effects might occur after systemic administra-
tion of BMP-7.
Possible Role for Other BMPs
Most of the antifibrotic potential of BMP-7 has been
attributed to its ability to antagonize the injurious effects
driven by TGF-β1. However, little is known about the
mechanism by which the interaction between these two
growth factors occurs. Interestingly, the protective effect of
BMP-7 on preservation of TGFβ1-induced downregulation of
E-cadherin expression in tubular epithelial cells could be
mimicked by transfection with the constitutively active
general BMP type I receptor ALK3 (47). Furthermore,
expression of thrombospondin-1 (TSP-1), which is the major
activator of latent TGF-β1 in experimental glomerulonephri-
tis and diabetic nephropathy, was repressed by the prototyp-
ical BMP target gene Id1 (68,69). These data suggest that
these antifibrotic effects are not entirely specific for BMP-7,
and that other BMPs might have similar anti-TGFβ1 activity.
In this respect, it is noteworthy that both BMP-4 and BMP-6
were able to functionally substitute for loss of BMP-7 during
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kidney development (70), and that BMP-6 could inhibit
TGFβ1-induced expression of CTGF and plasminogen acti-
vator inhibitor-1 in renal interstitial fibroblasts (71). Our
observations that myofibroblast progenitor cells derived from
patients with diabetes were deficient in BMP-6 expression (71),
and that in renal cortex of diabetic mice, BMP-4, -5, and -6
were decreased to a similar extent as BMP-7 (Fig. 1), indicate
that, in addition to BMP-7, also other BMPs might play an
important role as antagonists of renal fibrosis.
Despite apparent overlap in functions of other BMPs
with BMP-7, it should be kept in mind that distinct biological
effects have been attributed to different BMPs. For instance,
BMP-6 and BMP-7 exhibited differential and specific effects
on survival and outgrowth of neurons, and opposite effects of
BMP-2 and BMP-7 have been reported on renal branching
morphogenesis (72,73). Moreover, the inhibitory effect of
BMP-7 on vascular calcification was not observed with BMP-
2 and BMP-4, which were both shown to promote calcifica-
tion of vascular smooth muscle cells (74,75).
Modulators of BMP-7
The activity of BMP-7 in the kidney can be enhanced or
inhibited by extracellular modulators. Recently, kielin/chor-
din-like protein (KCP) was identified as a novel enhancer of
BMP signaling. KCP−/− mice, which have less pSmad1
protein, developed significantly more renal damage and
interstitial fibrosis after induction of UUO or acute tubular
necrosis (76). In addition, pSmad2 protein levels were
increased in KCP−/− mice, suggesting that the antifibrotic
effect of KCP also included inhibition of TGF-β1 activity
(77). Also, several extracellular modulators have been
identified that inhibit BMP-7 activity, including uterine
sensitization-associated gene (USAG)-1, which is abundantly
expressed in the kidney. USAG-1−/− mice had increased
pSmad1/5 protein levels and exhibited prolonged survival
and preserved renal function after cisplatin nephrotoxicity or
UUO. The renoprotection in these mice could be abolished
by administration of a neutralizing antibody against BMP-7
(78). Moreover, in mice with folic acid nephrotoxicity, the
renal expression of USAG-1 at day 7 correlated with serum
creatinine at day 14, suggesting that USAG-1 expression in a
kidney biopsy could be useful in predicting outcome (79).
Recently, SclerOSTin domain-containing-1 or SOSTDC1 was
identified as the human ortholog of USAG-1 and was shown
to be highly expressed in normal kidney, but downregulated
in renal clear cell carcinoma (80). Other antagonists of
BMP-7 in the kidney include gremlin and noggin, of which
overexpression of the latter in podocytes has been shown to
result in massive mesangial matrix expansion (81,82).
Taken together, these data indicate that the antifibrotic
BMP activity in the kidney is not determined by the
expression levels of BMP-7 alone, but that expression of
multiple other BMPs and BMP modulators might be equally
important. Moreover, the previously cited efficacy of inhibit-
ing TGF-β1 without BMP suppletion indicates that, more in
general, modulation of the balance between BMP- and TGF-
β1-signaling activity might be the key to restoration of
appropriate response to injury and reversal of fibrosis. In this
respect, a modulator of particular interest is CTGF, which is
able to both enhance TGFβ1 activity, and inhibit BMP-4
activity (83).
CTGF IS AN EXTRACELLULAR MODULATOR
OF MULTIPLE SIGNALING ACTIVITIES
Connective Tissue Growth Factor (CTGF; CCN-2)
CTGF was first identified in conditioned media of
endothelial cells as a 36–38 kDa cysteine-rich polypeptide
containing chemotactic and mitogenic activity towards fibro-
blasts (84). Subsequently, CTGF was acknowledged as a
member of the CCN (CTGF/Cyr61/Nov) family, and became
also known as CCN-2 (85). The CCN family consists of six
matricellular regulatory proteins, consistent with the notion
that they act by binding to extracellular signaling molecules
via their multiple distinct interaction domains, rather than by
signaling through direct binding to unique receptors specific
to individual CCNs (86).
Domain 1 of CTGF consists of an N-terminal insulin-like
growth factor binding protein, which is involved in binding of
CTGF to insulin-like growth factor (IGF)-1 and fibronectin
(87,88). Domain 2 of CTGF shares high homology with Von
Willebrand Factor type C repeats as well as with chordin, and
is responsible for binding of CTGF to TGF-β1 and BMP-4
(83). Domain 3 of CTGF contains a TSP-1 repeat and is
involved in binding to vascular endothelial growth factor
(VEGF), as well as binding to low-density lipoprotein
receptor-related protein (LRP)-1 and integrin α6β1 (89–91).
Domain 4 of CTGF is a C-terminal cysteine-rich domain. This
domain is involved in binding of CTGF to heparan sulfate
proteoglycans (HSPG), integrin αvβ3, fibronectin, and to the
Wnt co-receptor LRP-6 (88,92–94). Domain 4 is presumed to
also interact with the neurotrophin receptor TrkA, which leads
to induction of the transcription factor TGF-β-inducible early
gene (TIEG) (95). In addition, CTGF contains a cysteine-free
hinge region between domain 2 and 3, which is susceptible to
proteolytic cleavage by matrix metalloproteinases (MMP) and
other proteases (96).
Fig. 1. BMP-4, -5, -6, and -7 are similarly decreased in renal cortex of
diabetic mice. Diabetic nephropathy (DN) was induced in 12-week
old female C57Bl6/J mice by intraperitoneal injection with strepto-
zotocin (N=16). Renal cortex was harvested 9 weeks after induction.
Expression of BMP genes was assessed by quantitative PCR. Results
are expressed as mean±SD (*P<0.05).
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Functions of CTGF
The biological functions of CTGF are complex and
diverse. Importantly, CTGF is required for most of the
increased ECM production and other profibrotic activity
generally observed in response to TGF-β1 (97). In addition,
CTGF is critically involved in cell growth and differentiation,
migration, adherence, apoptosis and survival, as well as in
angiogenesis and chondrogenesis (98). Specific direct effects
of CTGF on renal cells include migration, hypertrophy,
fibronectin production, and actin disassembly in mesangial
cells, EMT and fibronectin production of tubular epithelial
cells, and collagen type III and TSP-1 production by renal
interstitial fibroblasts (99–104). Recently, a physiological role
for CTGF has been demonstrated in human corneal epithelial
cells, in which CTGF was required for regulation of re-
epithelialization (105).
Given its many and distinct interaction domains, it seems
likely that CTGF functions mainly as an extracellular
modulator of signaling activity of other growth factors. For
instance, upon binding of domain 1 to IGF-1, CTGF and IGF-
1 act synergistically to induce collagen type I and type III
production by renal interstitial fibroblasts (106). In contrast,
binding of CTGF to BMP-4 results in inhibition of BMP-4
signaling activity (83). Binding of CTGF to VEGF via domain
3 results in inhibition of VEGF-induced angiogenesis, and
this binding and inhibition are both lost upon cleavage of the
CTGF hinge region by MMP-1, -3, and -13 (96). Binding of
CTGF domain 3 to LRP-1 results in activation of ERK1/2
MAPK signaling, which can be inhibited by the LRP-1
antagonist receptor-associated protein (107). Furthermore,
simultaneous interaction of CTGF with HSPG and integrins
is essential for its role in adherence and migration, and
binding of CTGF domain 4 to LRP-6 suppresses Wnt-
signaling (92,108). Also, binding of CTGF to fibronectin via
domain 1 and domain 4 is important for the function of
CTGF in cell-matrix interactions (88,94).
Synergy between CTGF and TGF-β1
CTGF is not only induced by TGF-β1, but it is also a
major enhancer of the biological activity of TGF-β1. For
example, persistence of skin fibrosis in newborn mice was
achieved only after co-injection of both TGF-β1 and CTGF,
and not after injection of TGF-β1 or CTGF alone (109).
Anchorage-independent growth of rat fibroblasts and colla-
gen synthesis were also dependent on both TGF-β1 and
CTGF (110,111).
The synergy between CTGF and TGF-β1 might be
explained by several mechanisms (Fig. 2). In the first place,
physical interaction between TGF-β1 and domain 2 of CTGF
enhanced receptor binding and potentiated Smad-signaling
activity of TGF-β1 (83). In addition, binding to TrkA and
induction of TIEG, presumably by domain 4 of CTGF, might
interrupt the negative feedback loop of TGF-β1, since
Smad7, the major inhibitory Smad of the TGF-β1 signaling
pathway, is suppressed by TIEG (95). Finally, binding of
CTGF domain 3 to LRP-1 enhanced TGF-β1 responses,
including myofibroblast activation, de novo expression of α-
smooth muscle actin, and extracellular accumulation of
fibronectin. Remarkably, the latter effects were mediated by
ERK1/2 MAPK activation, without any evident modulation
of TGF-β1 induced phosphorylation of Smad2, or of pSmad2/
3 association with Smad4 (107).
It remains to be established whether synergy between
TGF-β1, TrkA, and LRP-1 derives entirely from their
individual interactions with separate CTGF domains per se.
In addition, cross-talk resulting from simultaneous interaction
of the distinct CTGF domains with their respective binding
partners might be relevant. This would be of interest with
respect to biological relevance of full length CTGF, as compared
to physiologically occurring CTGF cleavage products.
CTGF IS UPREGULATED IN RENAL FIBROSIS
CTGF Expression in Renal Fibrosis
Although development of the kidney is not affected in
CTGF−/− mice (112), the expression of CTGF is more
abundant in the normal adult kidney than in other organs
(113). In control human renal biopsies, CTGF mRNA is
mainly expressed in podocytes, and in some parietal epithelial
cells and interstitial cells. However, in renal biopsies of
patients with progressive glomerulopathies and tubulointer-
stitial damage, strong overexpression of glomerular and
tubulointerstitial CTGF mRNA was reported, of which the
latter correlated with the degree of damage (114). In
experimental and human crescentic glomerulonephritis,
CTGF was strongly overexpressed in areas with proliferating
glomerular parietal epithelial cells (115,116). Upregulation of
CTGF was also observed in experimental models of lupus
nephritis, anti-Thy-1.1-induced acute mesangial proliferative
glomerulonephritis, UUO, hypertensive nephrosclerosis, and
in the remnant kidney of 5/6 nephrectomized mice (117–121).
Furthermore, CTGF is critically involved in chronic allograft
nephropathy, in which CTGF expression was shown to be
highly expressed in tubular epithelial cells of the transplanted
Fig. 2. Mechanisms behind the synergy between CTGF and TGF-β1.
A Direct binding of TGF-β1 to domain 2 of CTGF enhances receptor
binding and potentiates signaling activity of TGF-β1 (83). B Direct
binding of CTGF, presumably via domain 4, to TrkA leads to
induction of TIEG with subsequent inhibition of Smad7, the major
inhibitory Smad of the TGF-β1 signaling pathway (95). Loss of
inhibitory Smad7 activity would lead to enhanced TGF-β1 signaling
activity. C Binding of CTGF domain 3 to LRP-1 enhances TGF-β1
responses by ERK1/2 MAPK activation (107).
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kidney, and in serum and urine of renal transplant recipients
(122,123).
CTGF in Diabetic Nephropathy
CTGF is considered to be of particular interest to
diabetic nephropathy. Already soon after its identification,
the expression of CTGF mRNA was shown to be strongly
upregulated in human mesangial cells cultured under high
glucose, and in renal biopsies of patients with diabetic
nephropathy (114,124). These observations were extended
in rodent models of both type 1 and type 2 diabetic
nephropathy (104,125,126). Furthermore, severity of diabetic
nephropathy was aggravated in transgenic mice with specific
overexpression of CTGF in podocytes (127). Upregulation of
CTGF was also confirmed in the diabetic myocardium, liver,
retina, and aorta (126,128–130). The potential use of CTGF
as a biomarker for renal damage in diabetes was assessed in
several clinical studies, in which soluble levels of CTGF were
increased in plasma and urine of patients with diabetic
nephropathy, and correlated with clinical markers of renal
disease (131–134). Moreover, in renal biopsies of patients
with type 2 diabetic nephropathy, tubular expression of
CTGF correlated with proteinuria, serum creatinine, and
interstitial fibrosis (135). Interestingly, CTGF expression was
shown to be decreased in microdissected glomeruli from renal
biopsies of patients with diabetic nephropathy, but this was
probably related to loss of podocytes (136).
Regulation of CTGF
TGF-β1 is the earliest recognized inducer of CTGF, and has
remained one of themost studied regulators of CTGF expression
in fibrotic processes (97,137). In addition, in vitro studies with
renal cells demonstrated that CTGF is also a direct target of
gene regulation by TGF-β1-independent factors including high
glucose, angiotensin II, aldosterone, hypoxia inducible factor-
1α, and cyclic mechanical strain (124,125,138–141). The 3′-
untranslated region of CTGF gene also contains regulatory
sequences, of which the activity depends on as yet largely
unidentified factors (142,143). In addition, several polymor-
phisms in the CTGF promoter region have been identified,
which might contribute to genetic susceptibility of patients to
develop fibrotic disorders (144–146). Of great interest, a G-
945C polymorphism in the promoter of CTGF was recently
shown to be associated with susceptibility to systemic sclerosis
(147). However, it remains to be established whether this
polymorphism is also associated with increased levels of CTGF
and susceptibility of patients to develop renal fibrosis.
CTGF IS A TARGET FOR ANTIFIBROTIC THERAPY
Inhibition of CTGF
CTGF is a downstream mediator of profibrotic TGF-β1
activity, and although one report has proposed a role of
CTGF in mediating TGF-β1 induced apoptosis in a breast
cancer cell line (148), there are no other reports of CTGF
involvement in the beneficial functions of TGF-β1 in anti-
inflammation and tumor suppression. In addition, restoration
of the balance between TGF-β1 and BMP signaling activity
seems more attractive than interference in a pathway that
also includes beneficial effects. Therefore, targeting CTGF in
fibrotic disorders, and renal fibrosis in particular, has been
proposed as a more suitable approach for antifibrotic
intervention than direct targeting of TGF-β1 (149,150).
In vitro, EMT of tubular epithelial cells could be
inhibited both by a homologous hexadeca-peptide of domain
4 of CTGF that recognizes αvβ3, and by CTGF knockdown
with antisense oligodeoxynucleotides (ODN) (151,152).
CTGF antisense ODN treatment also effectively reduced
expression of ECM genes and tubulointerstitial fibrosis in
experimental renal diseases, including UUO, the remnant
kidney model in TGF-β1 overexpressing mice, and in
dexamethasone-induced nephropathy (153–155).
CTGF Therapy in Diabetic Nephropathy
Recently, treatment with CTGF antisense ODN proved to
be successful in attenuation of proteinuria, and in reduction of
genes involved in mesangial matrix expansion in mouse models
of type 1 and type 2 diabetes (156). Interestingly, reduction of
albuminuria was also observed in diabetic db/db mice treated
with CTGF neutralizing antibody, and in diabetic CTGF+/−
mice harboring only one functional CTGF allele. These latter
two studies also showed that inhibition of CTGF in diabetic
nephropathy resulted in reduced thickening of the glomerular
basement membrane (Flyvbjerg et al., abstract J Am Soc
Nephrol 15:261A, 2004, and Nguyen et al., submitted). Anti-
CTGF treatment also reversed vascular stiffness and
microvascular leakage, improved cardiac function, and
normalized hypertension in type 1 diabetic rats (Langsetmo
et al., abstract Diabetes 55:A122, 2006). Moreover, a fully
human anti-CTGF antibody (FG3019) has been tested for
safety in phase 1 clinical trials in microalbuminuric type 1 and
type 2 diabetic patients. Administration of the antibody proved
to be well tolerated and was able to decrease urinary albumin
to creatinine ratio by 50% or more in 7 of 19 subjects (Adler
et al., abstract J Am Soc Nephrol 15:TH-PO239, 2004).
CONCLUSION
Renal fibrosis is the major determinant in progression of
acute and chronic kidney disease. TGF-β1 is the driving force
behind renal fibrosis and has since long been regarded as the
key factor to be targeted in prevention and treatment of renal
fibrosis. Considering its multiple effects, which are in part also
protective and beneficial, direct inhibition of general TGF-β1
activity might not be clinically applicable. Recently, BMP-7
and CTGF have emerged as novel modulators of profibrotic
TGF-β1 activity. In experimental models of renal disease,
especially in diabetic nephropathy, either administration of
BMP-7 or inhibition of CTGF have been sufficient to result in
striking improvement of renal function and structure. Target-
ing the profibrotic activity of both growth factors might occur
at several levels of their pathophysiological interaction with
other mediators, extracellular matrix, and cell surface mole-
cules. However, for both candidate therapeutics, assessment
of clinical applicability is still in an early phase of testing.
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